, Takashi Sasaki
, Takafumi Mie
, Takeshi Okamoto
, Chinatsu Mori
, Takaaki Furukawa
, Yuto Yamada
, Akiyoshi Kasuga
, Masato Matsuyama
, Masato Ozaka
, Naoki Sasahira
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Copyright © 2022 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Characteristic | DSOC-guided biopsy (n=39) | Tube-assisted biopsy (n=13) | p-value |
|---|---|---|---|
| Age (yr) | 73 (47–84) | 68 (52–86) | 0.505 |
| Male sex | 34 (87) | 7 (54) | 0.019 |
| Location of the stricture | 0.706 | ||
| Perihilar bile duct | 29 (74) | 11 (85) | |
| Distal bile duct | 10 (26) | 2 (15) | |
| Total bilirubin (mg/dL) | 1.1 (0.3–5.3) | 1.7 (0.4–10.8) | 0.153 |
| Prior history of ERCP, yes | 37 (95) | 10 (77) | 0.093 |
| Prior biliary stenting, yes | 36 (92) | 9 (69) | 0.057 |
| Papillary intervention | 0.250 | ||
| Endoscopic sphincterotomy | 39 (100) | 12 (92) | |
| Previously performed | 36 | 9 | |
| Performed | 3 | 3 | |
| None | 0 (0) | 1 (8) | |
| Operator experience (expert:trainee) | 22:17 | 8:5 | >0.999 |
| Procedure time (min) | 68 (35–126) | 55 (20–110) | 0.156 |
| Total number of biopsy sites | 148 | 45 | NA |
| Total number of biopsies | 280 | 78 | NA |
| Adverse events | 4 (10) | 2 (15) | 0.632 |
| Pancreatitis | 0 | 0 | |
| Cholangitis | 4 | 2 | |
| Cholecystitis | 0 | 0 | |
| Bleeding | 0 | 0 |
| Biopsy site | DSOC-guided biopsy |
Tube-assisted biopsy |
p-value | ||
|---|---|---|---|---|---|
| Patient | % (n /total) | Patient | % (n /total) | ||
| B2/B3 confluence | 12 | 50 (14/28) | 5 | 75 (6/8) | 0.257 |
| B4 confluence | 16 | 72 (23/32) | 7 | 67 (8/12) | 0.727 |
| Left hepatic duct | 10 | 63 (12/19) | 3 | 57 (4/7) | >0.999 |
| B5/B8 confluence | 10 | 52 (12/23) | 4 | 86 (6/7) | 0.193 |
| B6/B7 confluence | 2 | 0 (0/2) | 1 | 33 (1/3) | >0.999 |
| Anterior segmental duct | 4 | 29 (2/7) | 1 | 0 (0/3) | >0.999 |
| Posterior segmental duct | 8 | 33 (5/15) | 2 | 0 (0/3) | 0.522 |
| Confluence of anterior and posterior segmental ducts | 20 | 46 (17/37) | 2 | 100 (3/3) | 0.231 |
| Right hepatic duct | 7 | 67 (10/15) | 1 | 100 (2/2) | >0.999 |
| Confluence of right and left hepatic ducts | 24 | 69 (29/42) | 6 | 82 (9/11) | 0.482 |
| Upper bile duct | 6 | 67 (8/12) | 0 | NA | NA |
| Cystic duct confluence | 5 | 89 (8/9) | 2 | 67 (2/3) | 0.455 |
| Lower bile duct | 22 | 78 (28/36) | 11 | 81 (13/16) | >0.999 |
| Others | 2 | 100 (3/3) | 0 | NA | NA |
| Overall | 61 (171/280) | 69 (54/78) | 0.233 | ||
| Characteristic | DSOC-guided biopsy (n=27) | Tube-assisted biopsy (n=6) |
|---|---|---|
| Age (yr) | 73 (52–84) | 70 (53–85) |
| Male sex | 24 (89) | 2 (33) |
| Pathological diagnosis | ||
| Intrahepatic cholangiocarcinoma | 2 (7) | 0 |
| Hilar cholangiocarcinoma | 14 (52) | 2 (33) |
| Cystic duct carcinoma | 1 (4) | 2 (33) |
| Distal cholangiocarcinoma | 10 (37) | 2 (33) |
| Macroscopic type | ||
| Papillary | 2 (7) | 0 |
| Nodular | 8 (30) | 4 (67) |
| Flat | 15 (56) | 2 (33) |
| Mass-forming | 1 (4) | 0 |
| Unknown | 1 (4) | 0 |
| Total no. of biopsy sites | 108 | 18 |
| Total no. of evaluable biopsy sites | 106 | 16 |
| Variable | Overall (n=10) | Expert (n=4) | Trainee (n=6) | p-value |
|---|---|---|---|---|
| Visual impression (%) | ||||
| Sensitivity | 58 | 73 | 50 | 0.275 |
| Specificity | 95 | 96 | 92 | 0.597 |
| Positive predictive value | 82 | 80 | 83 | >0.999 |
| Negative predictive value | 85 | 94 | 70 | 0.004 |
| Diagnostic accuracy | 84 | 92 | 73 | 0.015 |
| Targeted biopsy (%) | ||||
| Sensitivity | 39 | 45 | 35 | 0.705 |
| Specificity | 97 | 98 | 96 | >0.999 |
| Positive predictive value | 86 | 83 | 88 | >0.999 |
| Negative predictive value | 79 | 89 | 65 | 0.008 |
| Diagnostic accuracy | 80 | 89 | 69 | 0.015 |
| Visual impression plus targeted biopsy (%) | ||||
| Sensitivity | 65 | 73 | 60 | 0.698 |
| Specificity | 97 | 98 | 96 | >0.999 |
| Positive predictive value | 91 | 89 | 92 | >0.999 |
| Negative predictive value | 87 | 94 | 75 | 0.018 |
| Diagnostic accuracy | 88 | 93 | 80 | 0.069 |
Values are presented as median (range) or number (%). DSOC, digital single-operator cholangioscopy; ERCP, endoscopic retrograde cholangiopancreatography; NA, not available.
DSOC, digital single-operator cholangioscopy; NA, not available.
Values are presented as median (range) or number (%). DSOC, digital single-operator cholangioscopy.
DSOC, digital single-operator cholangioscopy.
